Impact Factor

7.883 Call For Paper

Share on

Author(s):

B. D. TIWARI | S. R. MASHALE | T. S. PARDESHIMATH
Keywords:
Abstract:
For The Treatment Of Acid Reflux Disease (GERD), Functional Dyspepsia, And Acid Reflux Disorders, Doctors Frequently Prescribe The Fixed-dose Combination (FDC) Of Omeprazole, A Proton Pump Inhibitor (PPI), And Dopamine D2 Receptor Antagonist, Domperidone, Which Has Prokinetic And Antiemetic Effects. By Enhancing Stomach Motility And Decreasing Gastric Acid Secretion At The Same Time, This Combination Has A Synergistic Therapeutic Effect. However, Due To Differences In Formulation Design, Enteric Coating Technologies, And Manufacturing Standards, Different Marketed Formulations Of This FDC May Have Different Pharmaceutical Quality And Therapeutic Consistency. These Variations May Have A Major Effect On The Release Of The Drug, Its Bioavailability, And Eventually Its Clinical Effectiveness.

Download Article